Results 81 to 90 of about 2,835 (182)

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial [PDF]

, 2018
Background: At present, biological disease-modifying anti-rheumatic drugs (DMARDs) are the only treatment recommended for patients with ankylosing spondylitis who have not responded to first-line treatment with non-steroidal anti-inflammatory drugs ...
Maksymowych, Walter P, Mozaffarian, N., Maksymowych, W.P., Tseluyko, Vira, Meuleners, L., Baraliakos, Xenofon, Abi-Saab, W., Hendrikx, Thijs, Landewé, Robert, Deodhar, Atul, Gensler, Lianne S, Nadashkevich, Oleg, Baraliakos, X., Gensler, L.S., Abi-Saab, Walid, Liu, K., van der Heijde, D. sirée, Deodhar, A., Besuyen, R., Liu, Ke, van der Heijde, Désirée, Tasset, C., Hendrikx, T., Maksymowych, Walter P., Nadashkevich, O., Meuleners, Luc, Heijde, D. van der, Greer, Joy M, Besuyen, Robin, Landewe, R., Greer, J.M., Tseluyko, V., Gensler, Lianne S., Tasset, Chantal, Mozaffarian, Neelufar, Greer, Joy M.   +35 more
core   +1 more source

Positioning filgotinib in the therapeutic landscape of rheumatoid arthritis - alternative or complementary?

Ulusal Romatoloji Dergisi
Rheumatoid arthritis is a chronic inflammatory disease characterized by persistent immune activation and progressive joint damage. Although conventional and biological disease-modifying antirheumatic drugs have substantially improved disease control ...
Rukiye Menemencioğlu, Burcu Şahinbaş, Ahmet Altun   +2 more
doaj   +1 more source

Filgotinib effectiveness and safety as second or third-line therapy in patients with ulcerative colitis: data from a real-world study [PDF]

Intestinal Research
Background/Aims Real-world data on the use of filgotinib (FILGO) in patients with ulcerative colitis (UC) are limited. This study aims to provide consistent results on the effectiveness and safety of FILGO in treating UC.
Antonio Tursi, Giammarco Mocci, Francesco Costa, Linda Ceccarelli, Edoardo Savarino, Caterina De Barba, Caterina Mucherino, Elvira D’Antonio, Laura Montesano, Manuela Marzo, Franco Scaldaferri, Daniele Napolitano, Daniela Pugliese, Antonietta Gerarda Gravina, Raffaele Pellegrino, Rocco Spagnuolo, Francesco Luzza, Antonio Cuomo, Laura Donnarumma, Giovanni Maconi, Giovanni Cataletti, Lorenzo Bertani, Giorgia Bodini, Andrea Pasta, Simona Piergallini, Mariaelena Serio, Antonella Scarcelli, Pietro Capone, Fabio Cortellini, Stefano Rodino, Ladislava Sebkova, Giuliana Vespere, Silvia Sedda, Vittorio D’Onofrio, Leonardo De Luca, Federica Gaiani, Stefano Kayali, Cristiano Pagnini, Maria Giovanna Graziani, Maria Carla Di Paolo, Leonardo Allegretta, Alessia Immacolata Cazzato, Stefano Scorza, Antonio Ferronato, Davide Giuseppe Ribaldone, Giovanni Aragona, Patrizia Perazzo, Giacomo Forti, Michela Di Fonzo, Federico Iacopini, Roberta Pica, Claudio Cassieri, Francesca Maria Onidi, Paolo Usai Satta, Walter Elisei, Marcello Picchio, Alfredo Papa   +56 more
doaj   +1 more source

Correction to: Filgotinib: First Approval [PDF]

Drugs, 2021
Dhillon, Sohita, Keam, Susan J.
openaire   +1 more source

Interindividual variability and its impact on the effectiveness of Janus kinase inhibitors in rheumatoid arthritis treatment

Frontiers in Medicine
IntroductionAchieving the primary treat-to-target (T2T) goal in rheumatoid arthritis (RA) remains challenging for many patients, reflecting limitations in the effectiveness of existing treatments. Our study examines factors influencing Janus kinase (JAK)
Cristina Martinez-Molina, Cristina Martinez-Molina, Silvia Vidal, Silvia Vidal, Cesar Diaz-Torne, Cesar Diaz-Torne, Cesar Diaz-Torne, Hye S. Park, Hye S. Park, Hye S. Park, Hèctor Corominas, Hèctor Corominas, Hèctor Corominas   +12 more
doaj   +1 more source

[Cost per Responder Analysis of Filgotinib in Patients Suffering from Ulcerative Colitis] [PDF]

OBJECTIVE: To evaluate the costs and benefits associated with the use of biologics and Janus kinase inhibitors (JAKi) for the treatment of bio-experienced patients suffering from ulcerative colitis in Italy.METHODS: This pharmacoeconomic analysis ...
Pradelli, Lorenzo, Povero, Massimiliano, Castello, Luca, Visentin, Elena   +3 more
core   +1 more source

Experimental and Investigational Pharmacotherapy for Psoriatic Arthritis: Drugs of the Future

Journal of Experimental Pharmacology, 2020
Luca Navarini,1,* Damiano Currado,1,* Luisa Costa,2 Marco Tasso,2 Maria Sole Chimenti,3 Francesco Caso2 1Unit of Rheumatology, Immunology and Clinical Medicine, Università Campus Bio-Medico Di Roma, Rome, Italy; 2Rheumatology Unit, Department of ...
Navarini L, Currado D, Costa L, Tasso M, Chimenti MS, Caso F   +5 more
doaj  

Focus on Filgotinib in Rheumatoid Arthritis: A Trial-Based Review

Mediterranean Journal of Rheumatology
Janus kinases (JAK)/Signal Transducer and Activator of Transcription (STAT) pathway is involved in pathophysiologic cascade of a notable number of rheumatic diseases. The development of JAK inhibitors has expanded treatment choices in rheumatoid arthritis (RA) with a sustained class-effect efficacy.
Skouvaklidou, Elpida, Deligeorgakis, Dimitrios, Skalkou, Anastasia, Skepastianos, Vasileios, Tsafis, Konstantinos, Papadimitriou, Evdokia, Pagkopoulou, Eleni, Avgerou, Paraskevi, Mytilinaiou, Maria G, Tzitiridou-Chatzopoulou, Maria, Kougkas, Nikolaos, Adamichou, Christina   +11 more
openaire   +2 more sources

Refractory Pyostomatitis Vegetans With Multiple Aseptic Cutaneous Abscesses Successfully Treated With Filgotinib in Ulcerative Colitis

JEADV Clinical Practice
We report on a 31‐year‐old male patient diagnosed with active moderate‐to‐severe ulcerative colitis and a history of splenectomy. He was hospitalized due to confluent pustular oral lesions and multiple skin abscesses.
C. Dandoy, D. Franchimont, C. Delvaux, A. Buggenhout, D. Bernardi, V. Del Marmol, J. M. L. White   +6 more
doaj   +1 more source

Efficacy and safety of filgotinib in patients with moderately active rheumatoid arthritis and an inadequate response to methotrexate [PDF]

Objectives: Clinical trials restricted to moderately active RA are limited. Filgotinib is approved for treating moderate to severe active RA. This post hoc analysis assessed efficacy and safety of filgotinib in moderately active RA.
Taylor, Peter C, Buch, Maya H, Akroyd, Laura, Walker, David, Barry, Jane, Omoruyi, Edmund V Ekoka, Edwards, Christopher J   +6 more
core   +1 more source